Eli Lilly and Co.
(NYSE:LLY) on Sunday presented new analyses showing that women with obesity or overweight achieved significant weight loss with Foundayo across all stages of menopause.
The findings were based on post-hoc analyses involving more than 1,500 women enrolled in the ATTAIN-1 and ATTAIN-2 clinical trials and were presented at the American Diabetes Association's 86th Scientific Sessions.
Read Also: Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies Foundayo Shows Weight Loss In Menopausal Women According to the data, women treated with the highest dose of Foundayo experienced meaningful weight reductions over 72 weeks regardless of whether they were pre-, peri-, or post-menopausal.
In the ATTAIN-1 trial, women lost as much as 28.0 pounds (12.8%) before menopause, 30.4 pounds (14.4%) during menopause transition, and 28.2 pounds (14.1%) after menopause.
